2,4-diaminopyrimidines as potent inhibitors of trypanosoma brucei and identification of molecular targets by a chemical proteomics approach

PLoS Neglected Tropical Diseases

Volumn 5, Issue 2, 2011, Pages

  Mercer, Luke ^a   Bowling, Tana ^a   Perales, Joe ^a   Freeman, Jennifer ^a   Nguyen, Tien ^a   Bacchi, Cyrus ^b   Yarlett, Nigel ^b   Don, Robert ^c   Jacobs, Robert ^a   Nare, Bakela ^a  

^a SCYNEXIS Inc   (United States)

^b PACE UNIVERSITY   (United States)

^c Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PENTAMIDINE; SCYX 1120; SCYX 5070; SCYX 7434; SEPHAROSE; UNCLASSIFIED DRUG; 2,4 DIAMINOPYRIMIDINE; 2,4-DIAMINOPYRIMIDINE; ANTIPROTOZOAL AGENT; CYCLIN DEPENDENT KINASE; PROTEOME; PROTOZOAL PROTEIN; PYRIMIDINE DERIVATIVE;

AFFINITY CHROMATOGRAPHY; AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GEL ELECTROPHORESIS; IMMOBILIZATION; IN VITRO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PARASITE VIABILITY; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEOMICS; RAT; TRYPANOSOMA BRUCEI; ANIMAL; DISEASE MODEL; DRUG EFFECT; LEISHMANIA; METABOLISM; METHODOLOGY; MICROBIAL VIABILITY; PROTEIN BINDING; RODENT DISEASE; TIME;

ANIMALS; ANTIPROTOZOAL AGENTS; CDC2-CDC28 KINASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LEISHMANIA; MICE; MICROBIAL VIABILITY; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEOME; PROTEOMICS; PROTOZOAN PROTEINS; PYRIMIDINES; RODENT DISEASES; TIME FACTORS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 79952477411     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000956     Document Type: Article

References (36)

1. Simarro P, Cecchi G, Paone M, Franco J, Diarra A, et al. (2010) The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases Int J Health Geogr 9: 57.
2. Croft S, (1999) Pharmacological approaches to antitrypanosomal chemotherapy. Mem Inst Oswaldo Cruz, Rio de Janeiro 94: 215-220.
3. Burri C, Keiser J, (2001) Pharmacokinetic investigations in patients from northern Angola refractory to melasoprol treatment. Trop Med Int Health 6: 412-420.
4. Pépin J, Milord F, (1994) The treatment of human African trypanosomiasis. Adv Parasitol 33: 1-47.
5. Brun R, Schumacher R, Schmid C, Kunz C, Burri C, (2001) The phenomenon of treatment failures in human African trypanosomosis. Trop Med Int Health 6: 906-914.
6. Pays E, (1991) Antigenic variation and the problem of vaccines against African trypanosomes. Res Microbiol 142: 731-735.
7. Chu XJ, DiPinto W, Bartkovitz D, So SS, Vu BT, et al. (2006) Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 49: 6549-6560.
8. DePinto W, Chu XJ, Yin X, Smith M, Packman K, et al. (2006) In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 5: 2644-2658.
9. Denise H, Giroud C, Barrett MP, Baltz T, (1999) Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan. Eur J Biochem 259: 339-346.
10. Kuettel S, Mosimann M, Mäser P, Kaiser M, Brun R, et al. (2009) Adenosine Kinase of T. b. Rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)- 2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS Negl Trop Dis 25: e506.
11. Knockaert M, Gray N, Damiens E, Chang Y-T, Grellier P, et al. (2000) Intracellular targets of cyclin-dependent kinase inhibitore: identification by affinity chromatography using immobilised inhibitors. Chem Bio 7: 411-422.
12. Hirumi H, Hirumi K, (1989) Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 75: 985-989.
13. Wirtz E, Leal S, Ochatt C, Cross GAM, (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89-101.
14. Lanham S, (1968) Separation of trypanosomes from the blood of infected rats and mice by anion-exchangers. Nature 218: 1273-1274.
15. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, et al. (2003) An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol 130: 31-42.
16. Kapler GM, Coburn CM, Beverley SM, (1990) Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. Mol Cell Biol 10: 1084-1094.
17. Debrabant A, Joshi MB, Pimenta PF, Dwyer DM, (2004) Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol 34: 205-217.
18. Bacchi CJ, Brun R, Croft SL, Alicea K, Bühler Y, (1996) In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob. Agents Chemother 40: 144-153.
19. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, et al. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci 100: 15434-15439.
20. Quintavalle M, Sambuchin S, Summa V, Orsatti L, Talamo F, et al. (2007) Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J Biol Chem 282: 5536-5544.
21. Sirawaraporn W, Sertsrivanich R, Booth RG, Hansch C, Neal RA, et al. (1988) Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines. Mol Biochem Parasitol 31: 79-85.
22. Chowdhury SF, Guerrero RH, Brun R, Ruiz-Perez LM, Pacanowska DG, et al. (2002) Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J Enzyme Inhib Med Chem 17: 293-302.
23. Pez D, Leal I, Zuccotto F, Boussard C, Brun R, Croft SL, et al. (2003) 2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. Bioorg Med Chem 11: 4693-4711.
24. Jones A, Faldas A, Foucher A, Hunt E, Tait A, et al. (2006) Visualisation and analysis of proteomic data from the procyclic form of Trypanosoma brucei. Proteomics 6: 259-267.
25. Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, et al. (2005) Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 65: 6919-6926.
26. Brehmer D, Godl K, Zech B, Wissing J, Daub H, (2004) Proteome-wide Identification of Cellular Targets Affeted by Bisindolyleimide-type Protein Kinase C Inhibitors. Mol Cell Proteomics 3: 490-500.
27. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, et al. (2004) Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics 3: 1181-1193.
28. Jensen B, Sivam D, Kifer C, Myler P, Parsons M, (2009) Widespread variation in transcript abundance within and across developmental stages of Trypanosoma brucei. BMC Genomics 10: 482.
29. Siegel TN, Hekstra DR, Wang X, Dewell S, Cross GA, (2010) Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. Nucleic Acids Res 38: 4949-4957.
30. Wiese M, (2007) Leishmania MAP kinases- Familiar proteins in an unusual context Int J Parasitol 37: 1053-1062.
31. Bengs F, Scholz A, Kuhn D, Wiese M, (2005) LmxMPK9, a mitogen-activated protein kinase homologue affects flagellar length in Leishmania mexicana. Mol Microbiol 55: 1606-1615.
32. Hammarton T, (2007) Cell Cycle Regulation in Trypanosoma brucei. Mol Biochem Parasitol 153: 1-8.
33. Hammarton TC, Clark J, Douglas F, Boshart M, Mottram JC, (2003) Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin. J Biol Chem 278: 22877-22886.
34. Hammarton TC, Mottram JC, Doerig C, (2003) The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Prog Cell Cycle Res 5: 95-101.
35. Tu X, Wang CC, (2005) Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism. Eukaryotic Cell 4: 755-764.
36. Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, et al. (2004) Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother 48: 3033-3032.